Log in
Catecholamine vasopressor

Dopamine

Dopamine is an endogenous catecholamine with dose-dependent adrenergic and dopaminergic effects used primarily in the acute management of shock and hypotension. It acts as a direct sympathomimetic and indirect norepinephrine releaser. The most testable fact is its dose-dependent receptor selectivity: low doses activate dopaminergic receptors, moderate doses stimulate β1-adrenergic receptors, and high doses activate α1-adrenergic receptors.

Practice questionsHigh-yield facts
Drug classCatecholamine vasopressor and inotrope
MechanismDose-dependent dopaminergic, β1, and α1 receptor agonism
Main usesShock, hypotension, acute heart failure with hypoperfusion
Key adverse effectArrhythmias, tissue necrosis with extravasation
5 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Dopamine is a naturally occurring catecholamine that acts as a precursor to norepinephrine and epinephrine in the sympathetic nervous system. Its pharmacological effects are dose-dependent and result from activation of different receptor subtypes at varying concentrations.

Dose-dependent receptor activation:

  • Low doses (1–5 mcg/kg/min): Predominantly activate dopamine D1 and D2 receptors in renal, mesenteric, cerebral, and coronary vascular beds, causing vasodilation. This was historically thought to preserve renal perfusion, though clinical evidence does not consistently support "renal-dose dopamine" for preventing acute kidney injury.
  • Moderate doses (5–10 mcg/kg/min): Primarily stimulate β1-adrenergic receptors in the heart, increasing myocardial contractility (positive inotropy), heart rate (positive chronotropy), and cardiac output. Some α1 effect begins to emerge.
  • High doses (>10 mcg/kg/min): Predominantly activate α1-adrenergic receptors, causing vasoconstriction and increased systemic vascular resistance. At these doses, dopamine functions similarly to norepinephrine.

Dopamine also acts indirectly by promoting the release of norepinephrine from sympathetic nerve terminals. It is metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).

High-yield for exams
  • Dopamine has dose-dependent effects: low doses activate D1/D2 (vasodilation), moderate doses activate β1 (inotropy), high doses activate α1 (vasoconstriction).
  • Dopamine increases arrhythmia risk more than norepinephrine and is no longer first-line for septic shock.
  • Extravasation causes tissue necrosis; treat with phentolamine infiltration (Black Box Warning).
  • Renal-dose dopamine does not prevent or treat acute kidney injury and is not evidence-based.
  • Contraindicated with MAO inhibitors due to risk of hypertensive crisis.
  • Must correct hypovolemia before starting dopamine; it is ineffective in depleted intravascular volume.
  • Dopamine increases myocardial oxygen demand and may worsen ischemia in acute coronary syndromes.
  • Norepinephrine is preferred over dopamine in distributive shock per current guidelines.

Indications

Dopamine is used in acute care settings for hemodynamic support. Its use has declined in favor of norepinephrine for most shock states due to a higher arrhythmia risk.

Primary indications:

  • Cardiogenic shock: To increase cardiac output and blood pressure in patients with adequate filling pressures but poor myocardial contractility.
  • Distributive shock (septic shock): As an alternative vasopressor, though norepinephrine is preferred as first-line therapy according to current guidelines (Surviving Sepsis Campaign).
  • Symptomatic bradycardia: In hemodynamically unstable patients when atropine is ineffective or contraindicated, and external pacing is unavailable.
  • Acute heart failure with hypotension: To improve cardiac output and perfusion in patients with decompensated heart failure and low blood pressure.

Dopamine is administered as a continuous intravenous infusion via a central line due to the risk of tissue necrosis with peripheral extravasation.

Pharmacokinetics

Dopamine must be administered intravenously as it does not cross the blood-brain barrier in significant amounts and undergoes extensive first-pass metabolism if given orally.

  • Onset of action: 5 minutes after starting IV infusion.
  • Duration: 10 minutes after discontinuation; effects are short-lived due to rapid metabolism.
  • Metabolism: Rapidly metabolized by MAO and COMT in the liver, kidneys, and plasma to inactive metabolites (homovanillic acid and 3,4-dihydroxyphenylacetic acid).
  • Excretion: Metabolites are excreted in urine.
  • Half-life: Approximately 2 minutes.

The drug must be titrated carefully based on hemodynamic response, and continuous hemodynamic monitoring (arterial line, central venous pressure) is standard during infusion.

Adverse effects

Dopamine carries a significant risk of adverse cardiovascular effects, particularly at higher doses.

Common adverse effects:

  • Arrhythmias: Tachycardia, atrial fibrillation, ventricular ectopy, and ventricular tachycardia are common, especially in patients with underlying heart disease. Dopamine increases arrhythmia risk more than norepinephrine.
  • Tachycardia and palpitations: Due to β1-adrenergic stimulation.
  • Increased myocardial oxygen demand: May precipitate or worsen myocardial ischemia in patients with coronary artery disease.
  • Hypertension: Especially at high doses due to α1 vasoconstriction.
  • Tissue necrosis: Extravasation of dopamine into surrounding tissue causes vasoconstriction and ischemic necrosis. Phentolamine (an α-blocker) should be infiltrated locally if extravasation occurs.

Other effects:

  • Nausea and vomiting
  • Headache
  • Anxiety and restlessness
  • Gangrene of extremities (rare, with prolonged high-dose infusions or in patients with peripheral vascular disease)
  • Azotemia (increased renal vasoconstriction at high doses)

Black Box Warning: Dopamine has a Black Box Warning for tissue ischemia and necrosis due to extravasation. If extravasation occurs, the affected area must be promptly infiltrated with 10–15 mL of saline solution containing 5–10 mg of phentolamine (an α-adrenergic blocking agent) to prevent sloughing and necrosis.

Contraindications and warnings

Absolute contraindications:

  • Pheochromocytoma: Catecholamine excess can precipitate hypertensive crisis.
  • Uncorrected tachyarrhythmias or ventricular fibrillation: Dopamine will worsen arrhythmias.
  • Concurrent or recent (within 14 days) use of MAO inhibitors: Can cause prolonged and intensified effects, including hypertensive crisis.

Relative contraindications and warnings:

  • Hypovolemia: Must be corrected before or concurrently with dopamine administration; dopamine will not effectively raise blood pressure if intravascular volume is depleted.
  • Peripheral vascular disease: Risk of gangrene and limb ischemia with high doses or prolonged infusion.
  • Recent myocardial infarction: Increased myocardial oxygen demand may extend infarct size.
  • Sulfite allergy: Some formulations contain sodium metabisulfite, which can cause allergic reactions in sensitive individuals.

Pregnancy and lactation: Pregnancy category C. Use only if potential benefit justifies potential risk. It is unknown whether dopamine is excreted in breast milk.

Administration precautions: Must be given via a central venous catheter when possible. If peripheral access is used temporarily, monitor closely for signs of extravasation.

Drug interactions

Major interactions:

  • MAO inhibitors (phenelzine, selegiline, tranylcypromine): Prolong and intensify dopamine effects; may cause hypertensive crisis. Contraindicated.
  • Tricyclic antidepressants (amitriptyline, imipramine): Potentiate cardiovascular effects of dopamine, increasing risk of arrhythmias and hypertension.
  • Ergot alkaloids (ergotamine, methysergide): Risk of severe hypertension and peripheral vasoconstriction.
  • Phenytoin: IV phenytoin can cause hypotension and bradycardia; concurrent use with dopamine may result in seizures and severe hypotension.
  • Halogenated anesthetics (halothane, isoflurane): Sensitize the myocardium to catecholamines, increasing arrhythmia risk.

Other interactions:

  • β-blockers: May antagonize the cardiac effects of dopamine; α effects (vasoconstriction) may predominate, causing severe hypertension and reflex bradycardia.
  • α-blockers (phentolamine, prazosin): Antagonize the vasoconstrictive effects at high dopamine doses.
  • Diuretics: May have additive effects on increasing urine output at low dopamine doses, though clinical significance is debated.

Clinical pearls

  • Norepinephrine is preferred over dopamine in septic shock: The 2021 Surviving Sepsis Campaign guidelines recommend norepinephrine as the first-choice vasopressor because dopamine has a higher incidence of arrhythmias and may increase mortality in some subgroups.
  • "Renal-dose dopamine" is not evidence-based: Low-dose dopamine (1–3 mcg/kg/min) was historically used to improve renal perfusion and prevent acute kidney injury, but multiple randomized controlled trials have shown no benefit in preventing or treating acute renal failure.
  • Extravasation is a surgical emergency: If dopamine infiltrates into tissue, stop the infusion immediately, do not flush the line, and infiltrate the area with 5–10 mg of phentolamine diluted in 10–15 mL of saline within 12 hours to prevent necrosis.
  • Dopamine increases pulmonary artery pressure: It can worsen right ventricular afterload in patients with pulmonary hypertension or right heart failure.
  • Taper gradually when discontinuing: Abrupt cessation can cause rebound hypotension.
  • Dopamine is a poor choice in cardiogenic shock due to acute MI: Increased heart rate and contractility raise myocardial oxygen consumption, potentially extending infarct size. Dobutamine or mechanical support (IABP, Impella) may be better options.
  • Check for sulfite allergy: Many commercial dopamine solutions contain sodium metabisulfite as a preservative.

Practice questions

1. A 62-year-old man with a history of coronary artery disease is admitted to the ICU with septic shock. Despite adequate fluid resuscitation with 30 mL/kg crystalloid, his blood pressure remains 82/50 mmHg and his heart rate is 118 bpm. The intensivist starts an infusion of dopamine at 15 mcg/kg/min. Over the next hour, his blood pressure improves to 110/65 mmHg, but he develops frequent premature ventricular contractions on telemetry. Which of the following is the most appropriate next step?

Answer: C. Norepinephrine is the preferred first-line vasopressor in septic shock and has a lower risk of arrhythmias compared to dopamine. This patient developed ventricular ectopy on dopamine, a known complication due to β1 stimulation in the setting of underlying coronary disease. Switching to norepinephrine will provide effective vasopressor support with less arrhythmogenic potential. Increasing dopamine or adding dobutamine would worsen arrhythmia risk, and antiarrhythmics do not address the underlying cause (catecholamine-induced ectopy).

2. A 58-year-old woman is receiving dopamine via a peripheral IV line in the emergency department for distributive shock. The nurse notices swelling and blanching at the IV site. The infusion is immediately stopped. Which of the following is the most appropriate immediate treatment?

Answer: C. Dopamine extravasation causes local vasoconstriction and tissue ischemia, which can lead to necrosis. Phentolamine is an α-adrenergic antagonist that reverses the vasoconstrictive effects when infiltrated into the affected area (5–10 mg in 10–15 mL saline within 12 hours). This is the standard of care for catecholamine extravasation. Warm compresses, elevation, corticosteroids, and topical nitrates do not adequately reverse α-mediated vasoconstriction and are insufficient to prevent tissue damage.

3. A 45-year-old man with treatment-resistant depression is prescribed phenelzine by his psychiatrist. Two weeks later, he presents to the emergency department with severe hypotension after a motor vehicle accident. The trauma team considers starting dopamine for hemodynamic support. Which of the following best explains why dopamine is contraindicated in this patient?

Answer: C. Phenelzine is a monoamine oxidase inhibitor (MAOI). MAO is one of the primary enzymes that metabolizes dopamine. When MAO is inhibited, dopamine accumulation occurs, leading to prolonged and intensified sympathomimetic effects, including severe hypertension and potential hypertensive crisis. This combination is contraindicated. COMT (not blocked by MAOIs) is another metabolic pathway, but MAO inhibition alone is sufficient to cause dangerous dopamine accumulation. Norepinephrine would be a safer alternative vasopressor in this scenario, though it also requires caution with MAOIs.

Frequently asked questions

How does dopamine work?

Dopamine works through dose-dependent activation of different receptors. At low doses (1–5 mcg/kg/min), it activates dopamine D1 and D2 receptors causing vasodilation in renal and mesenteric beds. At moderate doses (5–10 mcg/kg/min), it stimulates β1-adrenergic receptors in the heart, increasing contractility and cardiac output. At high doses (>10 mcg/kg/min), it activates α1-adrenergic receptors, causing vasoconstriction and increased blood pressure. It also indirectly releases norepinephrine from nerve terminals.

What are the side effects of dopamine?

The most serious side effects are arrhythmias (tachycardia, atrial fibrillation, ventricular arrhythmias), which occur more frequently than with norepinephrine. Dopamine increases myocardial oxygen demand and can worsen ischemia. Extravasation causes tissue necrosis and requires immediate phentolamine infiltration. Other effects include tachycardia, hypertension, nausea, headache, anxiety, and rarely gangrene of extremities with prolonged high-dose use. It should not be used with MAO inhibitors due to risk of hypertensive crisis.

Is dopamine a controlled substance?

No, dopamine is not a controlled substance under the US Controlled Substances Act. It is a prescription medication used only in hospital settings for acute hemodynamic support in shock and hypotension. It must be administered as a continuous IV infusion under close monitoring and is not available for outpatient use.

Dopamine vs norepinephrine — what is the difference?

Dopamine has dose-dependent effects on multiple receptors (dopaminergic, β1, α1), while norepinephrine primarily acts on α1 and β1 receptors with potent vasoconstriction. Norepinephrine is now preferred over dopamine as first-line therapy in septic shock because dopamine carries a higher risk of tachyarrhythmias and may increase mortality. Dopamine increases heart rate more than norepinephrine. Norepinephrine produces more predictable vasoconstriction, while dopamine's effects vary by dose and are less titratable.

Why is renal-dose dopamine not recommended?

Renal-dose dopamine (low-dose dopamine at 1–3 mcg/kg/min) was historically used to improve renal perfusion and prevent acute kidney injury through dopamine receptor-mediated vasodilation. However, multiple randomized controlled trials and meta-analyses have shown no benefit in preventing or treating acute renal failure, reducing need for dialysis, or improving mortality. Current evidence does not support its routine use for renal protection, and it may still cause arrhythmias and other adverse effects.

Conditions it is used for

Cardiogenic shockSeptic shockDistributive shockHypotensionSymptomatic bradycardiaAcute heart failure
NorepinephrineEpinephrineDobutaminePhenylephrineVasopressinMilrinoneIsoproterenol

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: C01CA04

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.